BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol 2020;26:261-79. [PMID: 32536045 DOI: 10.3350/cmh.2020.0032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Kim SY, Lee HS, Bang SM, Han DH, Hwang HK, Choi GH, Chung MJ, Kim SU. Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:1828. [PMID: 33921232 DOI: 10.3390/cancers13081828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bianca C, Sidhartha E, Tiribelli C, El-Khobar KE, Sukowati CHC. Role of hepatitis B virus in development of hepatocellular carcinoma: Focus on covalently closed circular DNA . World J Hepatol 2022; 14(5): 866-884 [DOI: 10.4254/wjh.v14.i5.866] [Reference Citation Analysis]
3 Nagaoka K, Tanaka M, Tanaka Y. Mac-2 binding protein and its glycan isomer: Where does it come from? Where is it going? Hepatol Res 2021;51:1026-8. [PMID: 34596313 DOI: 10.1111/hepr.13697] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chang Y, Kim SG, Jeong SW, Jang JY, Yoo JJ, Lee SH, Kim YS, Kim HS, Lee HW, Park S. Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study. J Clin Med 2021;10:5628. [PMID: 34884330 DOI: 10.3390/jcm10235628] [Reference Citation Analysis]
5 Lee HA, Lee HW, Park Y, Kim HS, Seo YS. Hepatitis B Core-Related Antigen Is Useful for Predicting Phase and Prognosis of Hepatitis B e Antigen-Positive Patients. J Clin Med 2022;11:1729. [PMID: 35330053 DOI: 10.3390/jcm11061729] [Reference Citation Analysis]
6 Cerva C, Salpini R, Alkhatib M, Malagnino V, Piermatteo L, Battisti A, Bertoli A, Gersch J, Holzmayer V, Kuhns M, Cloherty G, Ferrari L, Laura C, Teti E, Cantonetti M, Arcese W, Ceccherini-silberstein F, Perno C, Andreoni M, Svicher V, Sarmati L. Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients. Biomedicines 2022;10:443. [DOI: 10.3390/biomedicines10020443] [Reference Citation Analysis]
7 Han S, Choi HJ, Beom SH, Kim HR, Lee H, Lee JS, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han KH, Seong J, Won JY, Kim BK. Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2021;147:3123-33. [PMID: 33893539 DOI: 10.1007/s00432-021-03632-4] [Reference Citation Analysis]
8 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel) 2021;14:417. [PMID: 34062711 DOI: 10.3390/ph14050417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hayashi S, Nagaoka K, Tanaka Y. Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins. Int J Mol Sci 2021;22:11051. [PMID: 34681709 DOI: 10.3390/ijms222011051] [Reference Citation Analysis]
10 Salpini R, Malagnino V, Piermatteo L, Mulas T, Alkhatib M, Scutari R, Teti E, Cerva C, Yu La Rosa K, Brugneti M, Bertoli A, Rossi B, Holzmayer V, Gersch J, Kuhns M, Cloherty G, Ceccherini-Silberstein F, Perno CF, Iannetta M, Andreoni M, Sarmati L, Svicher V. Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers. Microorganisms 2020;8:E1819. [PMID: 33218205 DOI: 10.3390/microorganisms8111819] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Roberts SK, Majeed A, Kemp W. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. Clin Liver Dis 2021;25:785-803. [PMID: 34593153 DOI: 10.1016/j.cld.2021.06.006] [Reference Citation Analysis]
12 Amano H, Kanda T, Mochizuki H, Kojima Y, Suzuki Y, Hosoda K, Ashizawa H, Miura Y, Tsunoda S, Hirotsu Y, Ohyama H, Kato N, Moriyama M, Obi S, Omata M. The Use of Electronic Medical Records-Based Big-Data Informatics to Describe ALT Elevations Higher than 1000 IU/L in Patients with or without Hepatitis B Virus Infection. Viruses 2021;13:2216. [PMID: 34835022 DOI: 10.3390/v13112216] [Reference Citation Analysis]
13 Lee HW, Park SY, Lee YR, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL. Am J Gastroenterol 2021. [PMID: 34506308 DOI: 10.14309/ajg.0000000000001497] [Reference Citation Analysis]
14 Lee JS, Lee HW, Lim TS, Shin HJ, Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. Cancers (Basel) 2021;13:5892. [PMID: 34885000 DOI: 10.3390/cancers13235892] [Reference Citation Analysis]
15 Cai Y, Yan J, Zhu L, Wang H, Lu Y. A Rapid Immunochromatographic Method Based on a Secondary Antibody-Labelled Magnetic Nanoprobe for the Detection of Hepatitis B preS2 Surface Antigen. Biosensors (Basel) 2020;10:E161. [PMID: 33142715 DOI: 10.3390/bios10110161] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Shin S, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis. Diagnostics 2022;12:441. [DOI: 10.3390/diagnostics12020441] [Reference Citation Analysis]
17 Luo Y, Dong Z, Qi S, Li W. Application of Health Education Model Based on Theory of Behavior Change in Nursing Care of Patients with Chronic Hepatitis B. Journal of Nanomaterials 2022;2022:1-7. [DOI: 10.1155/2022/1982554] [Reference Citation Analysis]
18 Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, Lau DTY. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol 2022; 28(2): 216-229 [DOI: 10.3748/wjg.v28.i2.216] [Reference Citation Analysis]
19 Peng F, Yuan H, Zhou Y, Wu S, Long Z, Peng Y. Diagnostic Value of Combined Detection via Protein Induced by Vitamin K Absence or Antagonist II, Alpha-Fetoprotein, and D-Dimer in Hepatitis B Virus-Related Hepatocellular Carcinoma. IJGM 2022;Volume 15:5763-73. [DOI: 10.2147/ijgm.s362359] [Reference Citation Analysis]
20 Lin WL, Hung JH, Huang W. Association of the Hepatitis B Virus Large Surface Protein with Viral Infectivity and Endoplasmic Reticulum Stress-mediated Liver Carcinogenesis. Cells 2020;9:E2052. [PMID: 32911838 DOI: 10.3390/cells9092052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
21 Peng YC, Xu JX, Zeng CF, Zhao XH, You XM, Xu PP, Li LQ, Qi LN. Operable hepatitis B virus-related hepatocellular carcinoma: gut microbiota profile of patients at different ages. Ann Transl Med 2022;10:477. [PMID: 35571398 DOI: 10.21037/atm-22-1572] [Reference Citation Analysis]
22 Lee HW, Ahn SH, Chan HL. Hepatitis B Core-Related Antigen: From Virology to Clinical Application. Semin Liver Dis 2021;41:182-90. [PMID: 33957693 DOI: 10.1055/s-0041-1723088] [Reference Citation Analysis]
23 Chen F, Wang J, Wu Y, Gao Q, Zhang S. Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy. Front Oncol 2022;12:822449. [DOI: 10.3389/fonc.2022.822449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Tseng TC. Another oral antiviral treatment, but still far away from hepatitis B virus cure. Clin Mol Hepatol 2021;27:281-2. [PMID: 33687857 DOI: 10.3350/cmh.2021.0072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Lee HW, Cho YY, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK, Park SY. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. Hepatol Int 2021;15:1083-92. [PMID: 34402025 DOI: 10.1007/s12072-021-10234-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
26 Lee HW, Lee HW, Lee JS, Roh YH, Lee H, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. J Hepatocell Carcinoma 2021;8:467-76. [PMID: 34079776 DOI: 10.2147/JHC.S300382] [Reference Citation Analysis]
27 Li Y, Wu S. Liver stiffness measured with two-dimensional shear wave elastography comparable to histopathology falls dominantly on the severe liver fibrosis. Clin Hemorheol Microcirc 2021. [PMID: 34334386 DOI: 10.3233/CH-211223] [Reference Citation Analysis]
28 Lee HW, Cho YY, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK, Park SY. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. J Viral Hepat 2021;28:1570-8. [PMID: 34435412 DOI: 10.1111/jvh.13601] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Ji JH, Park SY, Son WJ, Shin HJ, Lee H, Lee HW, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. External validation of CAGE-B and SAGE-B scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals. J Viral Hepat 2021;28:951-8. [PMID: 33763928 DOI: 10.1111/jvh.13506] [Reference Citation Analysis]